When was Inflammasome Therapeutics founded?

Inflammasome Therapeutics was founded in 2009 and raised its 1st funding round 11 years after it was founded.

Where is Inflammasome Therapeutics located?

Inflammasome Therapeutics is headquartered in Boston, United States.

How many employees does Inflammasome Therapeutics have?

As of Sep 30, 2026, the latest employee count at Inflammasome Therapeutics is 12.

Is Inflammasome Therapeutics a funded company?

Inflammasome Therapeutics is a funded company, having raised a total of $19.4M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 16, 2020.

When was the latest funding round of Inflammasome Therapeutics?

Inflammasome Therapeutics' latest funding was a $***** Series B round on Feb 27, 2026, with participation from 0 investor.

Where does Inflammasome Therapeutics rank among its competitors?

Inflammasome Therapeutics ranks 656th amongst 3512 active competitors, of which 1187 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Inflammasome Therapeutics?

Inflammasome Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Inflammasome Therapeutics - 2026 Company Profile, Funding & Competitors

Inflammasome Therapeutics is a series B company based in Boston (United States), founded in 2009. It operates as a Developer of therapeutic solutions for eye diseases and neural diseases. Inflammasome Therapeutics has raised $19.4M in funding. The company has 3512 active competitors, including 1187 funded and 835 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Inflam is a developer of therapeutic solutions for eye diseases. It has developed therapies for prevalent, degenerative diseases such as Alzheimer's disease, multiple sclerosis, macular degeneration, and type 2 diabetes.

Website: inflam.com
Email ID: *****@inflam.com

Key Metrics

Founded Year

2009

Location

Boston, United States

Stage

Series B

Total Funding

$19.4M in 5 rounds

Latest Funding Round

Series B, Feb 27, 2026, $*****

Investors

Gates

Ranked

656^th among 3512 active competitors

Employee Count

12 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 1401 more

View Inflammasome Therapeutics' full profile

Inflammasome Therapeutics has raised a total funding of $19.4M over 5 rounds. Its first funding round was on Sep 16, 2020. Inflammasome Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Inflammasome Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2026	5978249	Series B	7341003	2445563	5661299	6418102
Dec 02, 2024	6042098	Series A	2410456	1832629	8444245	9828621
Aug 04, 2023	8492935	Series A	4051266	8455399	7851854	9759545

Access funding benchmarks and valuations. Sign up today!

View details of Inflammasome Therapeutics's funding rounds and investors

Inflammasome Therapeutics' employee count trend

Inflammasome Therapeutics has 12 employees as of Sep 26. Here is Inflammasome Therapeutics's employee count trend over the years:

Employee count trend for Inflammasome Therapeutics

Uncover Inflammasome Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Inflammasome Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Inflammasome Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
656th	Inflammasome Therapeutics 2009, Boston (United States), Series B	Developer of therapeutic solutions for eye diseases and neural diseases	$19.4M	Gates	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Inflammasome Therapeutics's competitors? Click here to see the top ones

Inflammasome Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Inflammasome Therapeutics's sector:

Free

Diabetes - Sector Report

Edition: August, 2026 (66 Pages)

View all reports related to Inflammasome Therapeutics

Media has covered Inflammasome Therapeutics for a total of 3 events in the last 1 year, 2 of them have been about company updates and 1 about partnerships.